Aurinia Pharmaceuticals (AUPH) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 14% YoY to $83.7 million; nine-month revenue increased 19% to $244.6 million, and nine-month net income reached $103.5 million.

• Cash, cash equivalents, restricted cash and investments totaled $486.9 million at September 30, 2026; nine-month operating cash flow was $131.5 million.

• 2026 revenue guidance increased to $325M–$330M, while development advanced for PRESERVE and aritinercept.

Financial highlights

• Q3 net income was $31.7 million, flat YoY; nine-month net income was $103.5 million versus $76.4 million.

• Q3 operating income was $35.4 million versus $29.7 million; nine-month operating income was $123.1 million versus $71.7 million.

• Q3 SG&A declined to $24.7 million from $26.2 million YoY; R&D increased to $16.6 million from $8.4 million.

Outlook and guidance

• 2026 total revenue guidance rose from $315M–$325M to $325M–$330M; net product sales guidance narrowed from $305M–$315M to $310M–$315M.

• SG&A expense is expected to remain substantially consistent, while R&D expense is expected to increase as development progresses.

• Existing cash and operating cash flows are expected to fund operations under current plans; additional equity or debt financing may be pursued if needed.